Whole Exome Sequencing [WES] Market Analysis By Technology (synthesis, sequencing), By Products & Services (Instruments/Platforms/Sequencers, Kits, Sequencing Services and Data Analysis Services) 2014 To 2025

Exome sequencing, is a method for sequencing all the stated genes in an exome (also known as the genome). It is also known as complete exome sequencing (WES or WXS). It involves first choosing only the subdivision of DNA that encrypts proteins (known as exons) and at that time sequencing that DNA using any high-throughput DNA sequencing skill. A human being has about 180,000 exons, creating around 1% of the human genome, or around 30 million base pairs. The aim of this method is to classify hereditary differences that is accountable together Mendelian and common polygenic sicknesses for example Alzheimer's illness without any costs connected with whole-genome sequencing.

The market is segmented by products [Systems, Kits (Library Preparation, Target enrichment)], by services [Sequencing], by Technology [Sequencing by Synthesis], and by application [Cancer, Monogenic disorders]

Increasing acceptance of next generation sequencing methods for the prediction and treatment, monitoring of diverse chronic diseases for example cancer and other pathogenic infections. It is one of the high impression driver for the development in this business.

The worldwide whole exome sequencing market is sectioned on the base of technology, products and services, applications, end users, and geography.

Initiated on technology, the entire exome sequencing market is separated among sequencing by synthesis and sequencing in semiconductor. Founded on products and services, the entire exome sequencing market includes instruments/platforms/sequencers, kits, sequencing services and data analysis services. Entire exome sequencing kits are more categorized into DNA fragmentation, end repair, A-Tailing and size selection, library preparation kits and target enrichment kit.

Created on applications, the entire exome sequencing market is separated on diagnostics, drug discovery and development, personalized medicine, agriculture and animal research. The market, by end users, is categorized in investigation centers, educational and government organizations, hospitals and health center, and pharmacological and biotechnology businesses.

Technical progresses in sequencing arrangements, worldwide associations between important investigation organizations to enhance drug finding, and a rise in life science and R&D spending are the key features that are likely to push up the development of this market. Main issues that are restricting the progress of this market contain the high apparatus prices, the necessity for capable specialists, and high dependence on scholarships and funds.

On geography, the market is separated into North America, Europe, Asia, and Rest of the World (RoW). North America is the major market for whole exome sequencing. Europe and Asia stands for the second place. The Asian market is scheduled to raise at the maximum percentage over the subsequent five years.

North America is projected to sustain its leadership in the market in the next years. Developments in the North American market is expected to be pushed by the issues, for example, the growing use of exome sequencing in uncommon sickness investigation, improved government subsidy, and huge amount of sequencing-related discussions and yearly assemblies held by the U.S.

The major companies in the international whole exome sequencing market contain Ambry Genetics, Macrogen, Inc., Knome, Inc., Illumina, Inc., Life Technologies, Roche NimbleGen, Inc., Agilent Technologies, Sengenics,GENEWIZ, Inc., BGI (Beijing Genomics Institute), Eurofins Genomics, Inc., and others